Mochida Pharmaceutical Co., Ltd.

Toshinori Kanamori

Masahiro Nobuhara

Hideaki Morishita

Naofumi Sato

Hiroshi Mochizuki

Tadakazu Yamauchi

Ei Mochida

Kamon Shirakawa

Kiyoshi Yamaguchi

Shuzo Akiyama

Kenichiro Nakashima

Naotaka Kuroda

Process for specific binding assay for measuring the amount of analyte in a liquid test sample

DNA fragments having a nucleotide sequence represented by x and vectors containing the DNA fragment, wherein the nucleotide sequence x encodes an amino acid sequence represented by any one of the following formulae 1 to 8:

DNA fragment, vector containing the DNA fragment, transformant

This invention provides a novel polypeptide which comprises an amino acid sequence that constitutes a portion of urinary trypsin inhibitor (UTI) and which has no antigenicity against human and high activity to inhibit various proteases, as well as other novel polypeptides having excellent activities to inhibit various proteases obtained by mutation of the former novel polypeptide. This invention also provides novel enzyme inhibition processes, drug compositions and treating methods making use of the novel polypeptide, DNA fragments containing nucleotide sequences which encode the novel polypeptides, vectors containing the DNA fragments and transformants transformed with the DNA fragments or the vectors, as well as processes for the production of the novel polypeptides.

Isolated DNA encoding novel protease inhibitory polypeptide

A method for the measurement of adenyl group-containing substances which comprises deriving a chemiluminescent substance by allowing a compound to react with adenyl group in a substance to be measured, and qualitatively or quantitatively measuring the substance to be measured using a luminescent intensity obtained from the chemiluminescent substance as a marker.

Method for measuring adenyl group-containing susbstances

This invention particularly provides a novel polypeptide having high protease-inhibiting activity, preferably FXa-inhibiting activity, which comprises, at least as a part of the polypeptide, an amino acid sequence resulting from substitution of an amino acid for at least one amino acid in the following amino acid sequence (1), wherein the amino acid substitution is at least one substitution selected from the following substitution means (i) to (iii). It also provides a process for the production of the polypeptide, a novel DNA fragment encoding the polypeptide and a drug composition containing the same. Amino acid sequence (1) ##STR1## (i) Substitution of 15 position Gln counting from the N-terminus by an amino acid other than Gln.

Polypeptide, DNA fragment encoding the same, drug composition containing

Acridinium compounds represented by the general formula (I) where A is an intervening group which does not have activity for binding with a specific binding substance, Z is a labelling active group which has activity for binding with a specific binding substance, R.sup.1 is a halogen atom, an alkyl group or an aryl group; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each a hydrogen atom, an alkyl group, an aryl group, an alkoxy group, a nitro group, a halogen atom or a carbonyl group, and Y is a counter ion. The acridinium compounds may form conjugates with specific binding substances. The acridinium compounds have high emission efficiency and stability and, hence, are useful as chemiluminescence labelling agents.

Acridinium compounds and conjugates thereof

This invention particularly provides a novel polypeptide having high protease-inhibiting activity, preferably FXa-inhibiting activity, which comprises, an lease as a part of the polypeptide, an amino acid sequence resulting from substitution of an amino acid for at least one amino acid in the following amino acid sequence (1), wherein the amino acid substitution is at least one substitution selected from the following substitution means (i) to (iii). It also provides a process for the production of the polypeptide, a novel DNA fragment encoding the polypeptide and a drug composition containing the same.

A specific binding assay process which is useful for quick qualitative or quantitative measurement and which can be used for various purposes, and a specific binding assay device suitable for the practice of the process,

Electrochemical immunochromatographic assay

This invention particularly provides a novel polypeptide having high protease-inhibiting activity, preferably FXa-inhibiting activity, which comprises, at least as a part of the polypeptide, an amino acid sequence resulting from substitution of an amino acid for at least one amino acid in the following amino acid sequence (1), wherein the amino acid substitution is at least one substitution selected from the following substitution means (i) to (iii). It also provides a process for the production of the polypeptide, a novel DNA fragment encoding the polypeptide and a drug composition containing the same.

Protease inhibitory polypeptides derived from urinary trypsin inhibitor

A process for producing interferon comprises culturing interferon-producing mammalian cells in a cell culture medium containing at least one compound selected from the group consisting of ascorbic acid, an ascorbic acid derivative and a vanadium compound. According to the process of the present invention, interferon can be produced in large amounts.

Growing community of inventors

Tokyo, Japan

Toshinori Kanamori